Alzheimer Disease (AD)ALZNADNCT07127510
Brain NAD in Alzheimer's Disease
An observational study of Alzheimer Disease (AD), run by Florida Atlantic University at 1 site in United States.
Trial summary
The goal of this observational study is to learn about the levels of nicotinamide adenine dinucleotide (NAD) in the brains of people with Alzheimer's disease. The study aims to determine if brain NAD levels are lower in people with Alzheimer's disease compared with people of the same age group who do not have… Read more about this study
- Who is it for?
- Ages 65 to 80 yearsHealthy volunteers can take part
- Conditions the study is for
- Alzheimer Disease (AD)
- How many people
- 20 participants
- Where
- 1 siteUnited States
- Study dates
- 18 Mar 2026to 1 Jun 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 65 to 80 years
- All sexes
- Healthy volunteers accepted
- Older adult
Study population: Primary care clinic, community.
Who may be able to join
- Participants are able to come to the Florida Atlantic University Clinical Research Unit, are verbal and ambulatory.
- Age 65 to 80 included.
- People with Alzheimer's disease (AD): AD diagnosis established by the person's physician according to the following criteria: clinical diagnosis AND either positive amyloid PET-scan or FDA-approved positive CSF or blood test.
Who cannot join
- Under the age of 65 or over the age of 80.
- Advanced dementia such that the person would require sedation for undergoing an MRI scan.
- Receiving anti-amyloid intravenous treatments Leqembi or Kinsula.
- Having an MRI-incompatible pacemaker or other MRI-incompatible hardware (e.g. comprising a metallic part).
- Having a history of seizures.
- Working at night.
- Having cancer or having been diagnosed with cancer within the last 5 years (excluding superficial squameous or basal cell cancer).
- People with no AD: MoCA test result lower than 26.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
FAU Clinical Research Unit
Boca Raton, Florida, 33431
Judyta Kociolek, 5612974963, CRUDOR@health.fau.edu
About this study
Official title: Measurement of Brain NAD Levels in Alzheimer's Patients and Control Subjects by 1H-MRS
The goal of this observational study is to learn about the levels of nicotinamide adenine dinucleotide (NAD) in the brains of people with Alzheimer's disease. The study aims to determine if brain NAD levels are lower in people with Alzheimer's disease compared with people of the same age group who do not have Alzheimer's disease.
Participants with or without Alzheimer's disease will have a brain imaging session where NAD will be measured using magnetic resonance spectroscopy (MRS). Eight months later, they will have a second, similar, brain imaging session.
- Conditions
- Alzheimer Disease (AD)
- Keywords
- NAD, Alzheimer Disease (AD)
- Medical subject headings
- Alzheimer Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Alzheimer's disease group | People diagnosed with Alzheimer's disease | |
| Control group | People without Alzheimer's disease |
What is being measured
The primary outcome is the main question the study is designed to answer.
Brain NAD
NAD levels measured by 1H-MRS
Measured: At enrollment and 8 months after enrollment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Aug 2025
- Study start18 Mar 2026
- Primary completion1 Apr 2027 (estimated)
- Study completion1 Jun 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Alzheimer Disease (AD)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Florida Atlantic University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Corinne Lasmezas, Florida Atlantic University
- Investigators
- Corinne Lasmezas, PhD, Principal investigator, Florida Atlantic University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07127510
- Sponsor's protocol ID
- IRB2504137
- Acronym
- ALZNAD
- Status last verified
- Mar 2026
- First submitted
- 11 Aug 2025
- Last updated
- 24 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Primary outcome measure data will be shared.
Study at a glance
From the registry record, last updated by the sponsor on 24 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Measurement of Brain NAD Levels in Alzheimer's Patients and Control Subjects by 1H-MRS
- ClinicalTrials.gov ID
- NCT07127510
- Acronym / sponsor ID
- ALZNAD / IRB2504137
- Conditions
- Alzheimer Disease (AD)
- Keywords
- NAD, Alzheimer Disease (AD)
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- Florida Atlantic UniversityUniversity, hospital or other
- Study start
- 18 Mar 2026 (actual)
- Primary completion
- 1 Apr 2027 (estimated)
- Study completion
- 1 Jun 2027 (estimated)
- First posted
- 17 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to learn about the levels of nicotinamide adenine dinucleotide (NAD) in the brains of people with Alzheimer's disease. The study aims to determine if brain NAD levels are lower in people with Alzheimer's disease compared with people of the same age group who do not have Alzheimer's disease.
Participants with or without Alzheimer's disease will have a brain imaging session where NAD will be measured using magnetic resonance spectroscopy (MRS). Eight months later, they will have a second, similar, brain imaging session.
Study design
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Alzheimer's disease group | – | –People diagnosed with Alzheimer's disease |
| Control group | – | –People without Alzheimer's disease |
Who may qualify
- Ages
- 65 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Older adult
- Study population
- Primary care clinic, community.
Key inclusion criteria (3 listed)
- Participants are able to come to the Florida Atlantic University Clinical Research Unit, are verbal and ambulatory.
- Age 65 to 80 included.
- People with Alzheimer's disease (AD): AD diagnosis established by the person's physician according to the following criteria: clinical diagnosis AND either positive amyloid PET-scan or FDA-approved positive CSF or blood test.
Key exclusion criteria (8 listed)
- Under the age of 65 or over the age of 80.
- Advanced dementia such that the person would require sedation for undergoing an MRI scan.
- Receiving anti-amyloid intravenous treatments Leqembi or Kinsula.
- Having an MRI-incompatible pacemaker or other MRI-incompatible hardware (e.g. comprising a metallic part).
- Having a history of seizures.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Brain NAD
Time frame: At enrollment and 8 months after enrollment
NAD levels measured by 1H-MRS
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Mar 2026.
- Individual participant dataSharing planned: Yes. Primary outcome measure data will be shared.
Related trials for Alzheimer Disease (AD)
RecruitingObservational study
Effectiveness and Safety of Disease-Modifying Therapy for Alzheimer's Disease: A Multicenter Retrospective Study
Alzheimer's Disease (AD)
Active, not recruitingPhase 2
A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD)
Alzheimer's Disease
RecruitingPhase 1
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
Alzheimer s Disease, Mild Cognitive Impairment
RecruitingObservational study
Community-based Screening for Alzheimer's Disease
Alzheimer's Disease(AD), Mild Cognitive Impairment (MCI)
RecruitingObservational study
InRAD Observational Study
Alzheimer's Disease(AD), Mild Cognitive Impairment (MCI)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Corinne Lasmezas, PhD principal investigator
Florida Atlantic University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Alzheimer Disease (AD), run by Florida Atlantic University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 24 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact FAU Clinical Research Unit Central Contact (561-235-4467, CRUDOR@health.fau.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Brain NAD (time frame: At enrollment and 8 months after enrollment). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Mar 2026.